- Home
- TNGX vs TSHA Comparison
TNGX vs TSHA Comparison
Compare TNGX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- TSHA
- Stock Information
- Founded
- TNGX 2014
- TSHA 2019
- Country
- TNGX United States
- TSHA United States
- Employees
- TNGX N/A
- TSHA N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- TSHA Health Care
- Exchange
- TNGX Nasdaq
- TSHA Nasdaq
- Market Cap
- TNGX 317.4M
- TSHA 334.1M
- IPO Year
- TNGX N/A
- TSHA 2020
- Fundamental
- Price
- TNGX $1.96
- TSHA $1.79
- Analyst Decision
- TNGX Strong Buy
- TSHA Strong Buy
- Analyst Count
- TNGX 7
- TSHA 8
- Target Price
- TNGX $12.33
- TSHA $6.63
- AVG Volume (30 Days)
- TNGX 791.2K
- TSHA 1.6M
- Earning Date
- TNGX 05-07-2025
- TSHA 02-26-2025
- Dividend Yield
- TNGX N/A
- TSHA N/A
- EPS Growth
- TNGX N/A
- TSHA N/A
- EPS
- TNGX N/A
- TSHA N/A
- Revenue
- TNGX $42,069,000.00
- TSHA $8,333,000.00
- Revenue This Year
- TNGX N/A
- TSHA N/A
- Revenue Next Year
- TNGX N/A
- TSHA N/A
- P/E Ratio
- TNGX N/A
- TSHA N/A
- Revenue Growth
- TNGX 15.17
- TSHA N/A
- 52 Week Low
- TNGX $1.72
- TSHA $1.19
- 52 Week High
- TNGX $12.02
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- TNGX 37.66
- TSHA 60.47
- Support Level
- TNGX $1.80
- TSHA $1.69
- Resistance Level
- TNGX $2.01
- TSHA $1.79
- Average True Range (ATR)
- TNGX 0.21
- TSHA 0.11
- MACD
- TNGX 0.01
- TSHA 0.01
- Stochastic Oscillator
- TNGX 31.94
- TSHA 69.84
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.